Stock Track | PROCEPT BioRobotics Plunges 5.80% as 2026 Revenue Guidance Disappoints Despite Q3 Earnings Beat

Stock Track11-05

PROCEPT BioRobotics (PRCT) shares plummeted 5.80% in after-hours trading on Tuesday, despite the surgical robotics company reporting better-than-expected third-quarter results. The sharp decline appears to be driven by the company's 2026 revenue guidance, which fell short of investor expectations.

For the third quarter of 2025, PROCEPT BioRobotics reported revenue of $83.3 million, surpassing analysts' expectations of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also beat the estimated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking guidance.

While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, the company's newly issued fiscal year 2026 revenue guidance disappointed investors. PROCEPT projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential slowdown in growth rate appears to be the key factor behind the stock's significant after-hours decline, as investors had likely anticipated more aggressive growth projections for the coming year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150736847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150736847","market":"hk","top_or_hot":-1,"title":"Stock Track | PROCEPT BioRobotics Plunges 5.80% as 2026 Revenue Guidance Disappoints Despite Q3 Earnings Beat","media":"Stock Track","content":"<p>PROCEPT BioRobotics (PRCT) shares plummeted 5.80% in after-hours trading on Tuesday, despite the surgical robotics company reporting better-than-expected third-quarter results. The sharp decline appears to be driven by the company's 2026 revenue guidance, which fell short of investor expectations.</p>\n\n<p>For the third quarter of 2025, PROCEPT BioRobotics reported revenue of $83.3 million, surpassing analysts' expectations of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also beat the estimated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking guidance.</p>\n\n<p>While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, the company's newly issued fiscal year 2026 revenue guidance disappointed investors. PROCEPT projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential slowdown in growth rate appears to be the key factor behind the stock's significant after-hours decline, as investors had likely anticipated more aggressive growth projections for the coming year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | PROCEPT BioRobotics Plunges 5.80% as 2026 Revenue Guidance Disappoints Despite Q3 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | PROCEPT BioRobotics Plunges 5.80% as 2026 Revenue Guidance Disappoints Despite Q3 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PROCEPT BioRobotics (PRCT) shares plummeted 5.80% in after-hours trading on Tuesday, despite the surgical robotics company reporting better-than-expected third-quarter results. The sharp decline appears to be driven by the company's 2026 revenue guidance, which fell short of investor expectations.</p>\n\n<p>For the third quarter of 2025, PROCEPT BioRobotics reported revenue of $83.3 million, surpassing analysts' expectations of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also beat the estimated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking guidance.</p>\n\n<p>While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, the company's newly issued fiscal year 2026 revenue guidance disappointed investors. PROCEPT projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential slowdown in growth rate appears to be the key factor behind the stock's significant after-hours decline, as investors had likely anticipated more aggressive growth projections for the coming year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRCT","symbol_name":"PROCEPT BioRobotics","start_time":0,"source_url":"","article_id":"1150736847","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150736847","pubTimestamp":1762306383,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"PROCEPT BioRobotics (PRCT) shares plummeted 5.80% in after-hours trading on Tuesday, despite the surgical robotics company reporting better-than-expected third-quarter results. The sharp decline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"translate_title":"股票追踪|PROCEPT BioRobotics暴跌5.80%，尽管第三季度盈利超出预期，但2026年收入指引令人失望","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRCT":1},"content_text":"PROCEPT BioRobotics (PRCT) shares plummeted 5.80% in after-hours trading on Tuesday, despite the surgical robotics company reporting better-than-expected third-quarter results. The sharp decline appears to be driven by the company's 2026 revenue guidance, which fell short of investor expectations.\nFor the third quarter of 2025, PROCEPT BioRobotics reported revenue of $83.3 million, surpassing analysts' expectations of $80.9 million. The company's adjusted EBITDA loss of $7.4 million also beat the estimated loss of $10.2 million. However, these positive results were overshadowed by the company's forward-looking guidance.\nWhile PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, the company's newly issued fiscal year 2026 revenue guidance disappointed investors. PROCEPT projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential slowdown in growth rate appears to be the key factor behind the stock's significant after-hours decline, as investors had likely anticipated more aggressive growth projections for the coming year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150736847","isCrawlerRequest":true}